Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
A number of healthcare companies are seeking to capitalize on the recovering market conditions by...
Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...
Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration
Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...
Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation
Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into...
BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...
Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D
Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered...
Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...
Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients
Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...
China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan
The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...
Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...
CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products
Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...
Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...
Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...